Home
Drugs
Venetoclax
Clinical Trials

Clinical Trials Related to Venetoclax

Related studies linked through entity extraction aliases.

A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

Status: NOT_YET_RECRUITING
Phase: PHASE3

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

Status: RECRUITING
Phase: PHASE2

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Status: NOT_YET_RECRUITING
Phase: PHASE2

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Status: RECRUITING
Phase: EARLY_PHASE1

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

Status: RECRUITING
Phase: PHASE4

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Status: RECRUITING
Phase: PHASE1

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Status: RECRUITING
Phase: PHASE2

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Status: RECRUITING
Phase: PHASE2

Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

Status: RECRUITING
Phase: PHASE2

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

Status: RECRUITING
Phase: PHASE2

Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations

Status: RECRUITING
Phase: PHASE2

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Status: RECRUITING
Phase: PHASE3

Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

Status: RECRUITING
Phase: PHASE2

Use of Venetoclax , AML , Sohag , Egypt

Status: COMPLETED
Phase: N/A

Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage

Status: NOT_YET_RECRUITING
Phase: NA

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Status: RECRUITING
Phase: PHASE2

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Status: RECRUITING
Phase: PHASE3

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Status: RECRUITING
Phase: PHASE2

A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

Status: WITHDRAWN
Phase: PHASE2